Astera Labs entered this week as a stock that had already doubled in a month. It leaves the week with the Street rushing to catch up after a clean earnings beat sent shorts covering and analysts hiking targets en masse.
The catalyst was a Q1 print that landed on May 5. Adjusted EPS came in at $0.61, topping the $0.54 estimate. Revenue hit $308.4M, above the $292.2M consensus. Then came Q2 guidance of $355M–$365M in sales against a Street estimate of $310.6M — a roughly 15–17% beat on the outlook. The stock jumped 7.2% on May 5 alone, and is up 17.7% on the week to $215.69. That adds to an extraordinary 84% gain over the past month.
Short sellers have been unwinding ahead of and through the print. Short interest has fallen 13.6% over the past month, dropping to 7.5% of the free float from what was close to 10% in mid-April. The unwind has been sustained and orderly rather than a single-day panic. Availability has simultaneously loosened — borrow availability improved as shorts returned shares, and cost to borrow eased to 0.45%, down nearly 18% on the week. The ORTEX short score has drifted from around 51 in late April to 46.2 now, and ranks in just the 31st percentile of the universe. Bears have clearly been squeezed by the price action, but the remaining short interest at 7.5% of float still represents a meaningful overhang should sentiment turn.
Options traders moved more cautiously on the day of the print. The put/call ratio edged up to 0.88, nearly 2.7 standard deviations above its 20-day mean of 0.82 — the most defensive reading in months despite the bullish tape. That divergence is worth noting: even as the stock surged, options participants added more puts than usual relative to calls, suggesting some hedging of gains rather than pure momentum chasing.
The analyst response has been swift and nearly unanimous in direction. JP Morgan's Harlan Sur raised his target to $280 (from $205) while maintaining Overweight. Morgan Stanley moved to $240 from $210. RBC went to $270 from $250. Citigroup lifted to $245, Stifel to $260, and Needham to $260. The mean Street target now stands at $241.38 — still around 12% above the current price, leaving the setup constructive even after the run. TD Cowen held at Hold but took its target to $225. Susquehanna stayed Neutral but bumped to $230 from $155 — a wide revision that illustrates how much the quarter moved consensus expectations. Two new initiations in recent weeks (Rothschild at Neutral/$153, UBS at Neutral/$180) sit well below the current price, likely reflecting targets set before the earnings step-change; those figures appear dated relative to the post-print reality. At a P/E of 74 and EV/EBITDA of 53, the stock is priced for continued hyper-growth, and the EV/EBIT factor ranks in just the 11th percentile — the Street is paying a significant premium for Astera's AI connectivity story.
The insider picture is more nuanced. CEO and Founder Jitendra Mohan was a seller in April, offloading shares across multiple transactions around $170–$175 in mid-to-late April, totalling over $30M in the fortnight before the print. Independent Director Stefan Dyckerhoff also sold across the same window. Net insider activity over 90 days runs to over $92M of net selling. On paper this looks bearish, but the timing — at prices 20% below the post-earnings level — means insiders were selling into what proved to be the runway before a major rally. FMR (Fidelity) remained the largest institutional holder at 14.4% of shares, adding nearly 1.3 million shares in Q1. BlackRock added 1.7 million shares through April.
On a peer basis, the move was genuinely standout. CRDO — the closest correlated peer — rose 16.7% on the week, nearly matching ALAB's 17.7%. AVGO gained 6.9%. AMD added 9.9%. ALAB's outperformance reflects the specific catalyst rather than a sector-wide bid. Notably, NVDA — often grouped with AI chip names — slipped 7.8% on the week, underscoring that the ALAB print was stock-specific.
What to watch next: with no confirmed next earnings event in the data, the focal point shifts to whether guidance momentum holds through the quarter. The remaining short base at 7.5% of float keeps a potential squeeze dynamic alive if datapoints continue to beat — but the pace of short covering will depend heavily on whether Q2 execution matches the raised bar the guidance has now set.
See the live data behind this article on ORTEX.
Open ALAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
